Axsome Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +63.9%
EBITDA: +34.1%
EBIT: +35.0%
EPS: +35.4%
Free cash flow: +40.1%
Operating cash flow: +40.2%

Forward estimates

Revenue: +75.6%
EBITDA: —
EPS: +155.5%

Three-year CAGR

Revenue: +133.7%
EBITDA: +38.3%
EBIT: +39.7%
Net income: +36.2%
EPS: +38.6%
Free cash flow: +27.0%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.